A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
Administered By
Awarded By
Contributors
- Malcolm, William Ferris Principal Investigator
Start/End
- November 15, 2019 - December 31, 2021